AbbVie Signs an Exclusive Worldwide Research Collaboration with Voyager Therapeutics for Vectorized Abs
Shots:
- Voyager to receive $65M upfront and will be responsible for research- IND submission and onset of P-I trial for targets provided by AbbVie. AbbVie to get a WW option to license rights to futher develop and commercialize one or more vectorized alpha-synuclein Abs for Parkinson's and other synucleinopathies
- If AbbVie exercises its option to license- Voyager will receive $245M as P-I option- $1.2B milestones including regulatory & commercial sales and royalties on global sales of products
- Voyager’s technology is an AVV gene therapy technology enabling the development of therapies utilizing blood-brain barrier penetrant AVV capsids in neurological disorders including Parkinson's disease- Alzheimer's disease- Huntington's disease & Friedreich's ataxia
Ref: AbbVie | Image:AbbVie
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com